FIELD: cell biology; medicine.
SUBSTANCE: present invention relates to cell biology and medicine, in particular to the use of compositions with or without albumin that inhibit or reduce the probability of epithelial-mesenchymal transition (hereinafter – EMT) for the treatment of various diseases selected from hemorrhage, hypovolemia, burn, acute liver failure, liver dysfunction, hypoalbuminemia, acute respiratory failure syndrome in adults, liver cirrhosis, hemolytic disease of newborns, surgery in conditions of artificial blood circulation, nephrosis, cancer, hepatorenal syndrome, sepsis, organ perfusion or organ reperfusion. Compositions contain an EMT-inhibiting agent and do not contain or contain a low concentration of an EMT-stimulating agent. At the same time, a ratio of the EMT-stimulating agent to the EMT-inhibiting agent ranges from 7:3 to 0:10. Octanoic acid, octanoic acid salt or a combination thereof is used as the EMT-stimulating agent, and C9-C14 fatty acid, C9-C14 fatty acid salt, C9-C14 fatty acid monoglyceride, C9-C14 fatty acid triglyceride or a combination thereof is used as the EMT-inhibiting agent. The concentration of the EMT-stimulating agent is less than 0.08 millimoles per gram of albumin, if albumin is present in the composition, or less than 0.02 M, if the composition does not contain albumin. In case, when the EMT-stimulating agent and the EMT-inhibiting agent in the composition are fatty acids, they are different fatty acids or are part of triglyceride.
EFFECT: present invention makes it possible to reduce or inhibit EMT in a subject for whom EMT stimulation would have a negative effect.
35 cl, 7 dwg, 2 tbl, 8 ex
